These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3659003)

  • 1. Ketoconazole high dose (H.D.) in the management of hormonally pretreated patients with progressive metastatic prostate cancer.
    Debruyne FM; Witjes FA
    Prog Clin Biol Res; 1987; 243A():301-13. PubMed ID: 3659003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group.
    Witjes FJ; Debruyne FM; Fernandez del Moral P; Geboers AD
    Urology; 1989 May; 33(5):411-5. PubMed ID: 2652864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of high-dose ketoconazole on patients who have androgen-independent prostatic cancer.
    Eichenberger T; Trachtenberg J
    Can J Surg; 1989 Sep; 32(5):349-52. PubMed ID: 2475237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
    J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.
    Wilkinson S; Chodak G
    Eur Urol; 2004 May; 45(5):581-4; discussion 585. PubMed ID: 15082199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
    Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
    Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
    J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
    Eklund J; Kozloff M; Vlamakis J; Starr A; Mariott M; Gallot L; Jovanovic B; Schilder L; Robin E; Pins M; Bergan RC
    Cancer; 2006 Jun; 106(11):2459-65. PubMed ID: 16615097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ketoconazole in the treatment of advanced cancer of the prostate: experience with 14 patients].
    Castillo Cádiz O; Martínez Sanz P
    Rev Med Chil; 1985 Apr; 113(4):309-11. PubMed ID: 3835638
    [No Abstract]   [Full Text] [Related]  

  • 10. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
    Small EJ; Baron AD; Fippin L; Apodaca D
    J Urol; 1997 Apr; 157(4):1204-7. PubMed ID: 9120902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [High dosage ketoconazole therapy in the treatment of advanced prostatic cancer].
    Flamm J; Sagaster P; Teich G; Köhn H; Miksche M
    Urologe A; 1988 Mar; 27(2):111-6. PubMed ID: 3376369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose ketoconazole therapy in patients with metastatic prostate cancer.
    Tapazoglou E; Subramanian MG; Al-Sarraf M; Kresge C; Decker DA
    Am J Clin Oncol; 1986 Oct; 9(5):369-75. PubMed ID: 2946219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.
    González-Barcena D; Schally AV; Vadillo-Buenfil M; Cortez-Morales A; Hernández L V; Cardenas-Cornejo I; Comaru-Schally AM
    Prostate; 2003 Aug; 56(3):183-91. PubMed ID: 12772187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose ketoconazole to untreated stage D prostate cancer.
    Aabo K; Kjaer M; Hansen HH
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):431-7. PubMed ID: 3383945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
    Small EJ; Halabi S; Dawson NA; Stadler WM; Rini BI; Picus J; Gable P; Torti FM; Kaplan E; Vogelzang NJ
    J Clin Oncol; 2004 Mar; 22(6):1025-33. PubMed ID: 15020604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
    Scholz M; Jennrich R; Strum S; Brosman S; Johnson H; Lam R
    J Urol; 2005 Jun; 173(6):1947-52. PubMed ID: 15879788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
    Figg WD; Liu Y; Arlen P; Gulley J; Steinberg SM; Liewehr DJ; Cox MC; Zhai S; Cremers S; Parr A; Yang X; Chen CC; Jones E; Dahut WL
    J Urol; 2005 Mar; 173(3):790-6. PubMed ID: 15711271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.